Ozempic is the version of Novo Nordisk's semaglutide drug aimed at people with diabetes. Credit: K KStock/Adobe Stock
Wegovy and other GLP-1 obesity and blood sugar control drugs accounted for 17% of pharmacy benefits spending at CBIZ employer clients with self-funded health plans in 2024, up from 13% in 2023, according to a new health care report.
The broker's clients spent spent $125 million on GLP-1 agonist drugs. That's up from $81 million in 2023 and $42 million in 2022.
Recommended For You
Ozempic, a GLP-1 agonist classified officially as a drug for fighting diabetes, was the most popular drug in the GLP-1 category. About 6,500 participants in CBIZ plans were using that drug.
The other top-five GLP-1 agonists were Mounjaro, Wegovy, Zepbound and Trulicity.
In a separate benefits benchmarking report, CBIZ said that the typical employer client with 1 to 99 employees and preferred provider organization coverage spent $9,119 per employee for individual coverage and $24,842 for family coverage.
At employers with 100 or more employees, the average per-employee spending for all kinds of coverage was $8,435 for an individual and $23,968.
Related: GLP-1 medications fuel $806B U.S. prescription drug spending spree
CVIZ is a Cleveland-based professional services firm with about 4,500 benefit plan clients.
The CBIZ report is a part of a wave of GLP-1 data sources now emerging.
The International Foundation of Employee Benefit Plans said that 36% of the employers it surveyed now cover GLP-1 agonists for both weight-loss and diabetes, up from 34% in 2024.
Fair Health said the percentage of overweight or obese patients who received a GLP-1 prescription increased to about $11% in 2024, from 2.5% in 2019.
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Allison Bell
Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.
